This stock is no longer traded. It was delisted on August 14, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win technology platform. This platform represents a novel approach to cancer immunotherapy, designed to activate naturally occurring T cells that target both tumor cells and key immunosuppressive mechanisms within the tumor microenvironment, including cells expressing indoleamine 2,3-dehydrogenase (IDO), programmed death-ligand 1 (PD-L1), arginase 1, and TGF-β. The company's lead product candidate, IO102-IO103, also known as Cylembio, is in phase 3 clinical development for melanoma in combination with PD-1 inhibitors and is being evaluated in phase 2 trials for lung, head and neck cancers. Additional candidates include IO112, targeting arginase 1 in tumors associated with myeloid-derived suppressor cells such as renal cell carcinoma, breast, pancreatic, and prostate cancers, and IO170 for solid tumors. IO Biotech, Inc. focuses on off-the-shelf vaccines to address difficult-to-treat cancers across multiple solid tumor types. Founded in 2014 and headquartered in Copenhagen, Denmark, the company operates in the biotechnology sector, advancing immune-modulatory therapies to potentially enhance combination cancer treatments.
WebsiteOle MaalOees Vej 3
Copenhagen, 2200
Denmark
Summary of Apr 8's posts. Generated by AI.
Summary of Apr 7's posts. Generated by AI.
Summary of Nov 30's posts. Generated by AI.
Summary of Jan 23's posts. Generated by AI.
Investors talking about IOBT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.